KR20130110179A - Ｉｌ―17 길항제를 사용하는 건선의 치료 방법 - Google Patents

Ｉｌ―17 길항제를 사용하는 건선의 치료 방법 Download PDF

Info

Publication number
KR20130110179A
KR20130110179A KR1020137011792A KR20137011792A KR20130110179A KR 20130110179 A KR20130110179 A KR 20130110179A KR 1020137011792 A KR1020137011792 A KR 1020137011792A KR 20137011792 A KR20137011792 A KR 20137011792A KR 20130110179 A KR20130110179 A KR 20130110179A
Authority
KR
South Korea
Prior art keywords
binding molecule
patient
psoriasis
treatment
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137011792A
Other languages
English (en)
Korean (ko)
Inventor
아힘 구에트네르
마티아스 마하체크
샤리스 파파바실리스
올리베르 산데르
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44759699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20130110179(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20130110179A publication Critical patent/KR20130110179A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020137011792A 2010-10-08 2011-10-07 Ｉｌ―17 길항제를 사용하는 건선의 치료 방법 Ceased KR20130110179A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39138810P 2010-10-08 2010-10-08
US61/391,388 2010-10-08
PCT/EP2011/067522 WO2012045848A1 (en) 2010-10-08 2011-10-07 Methods of treating psoriasis using il-17 antagonists

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020147018691A Division KR101620771B1 (ko) 2010-10-08 2011-10-07 Ｉｌ―17 길항제를 사용하는 건선의 치료 방법
KR1020147036815A Division KR20150018595A (ko) 2010-10-08 2011-10-07 Ｉｌ―17 길항제를 사용하는 건선의 치료 방법

Publications (1)

Publication Number Publication Date
KR20130110179A true KR20130110179A (ko) 2013-10-08

Family

ID=44759699

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020137011792A Ceased KR20130110179A (ko) 2010-10-08 2011-10-07 Ｉｌ―17 길항제를 사용하는 건선의 치료 방법
KR1020147036815A Withdrawn KR20150018595A (ko) 2010-10-08 2011-10-07 Ｉｌ―17 길항제를 사용하는 건선의 치료 방법
KR1020147018691A Active KR101620771B1 (ko) 2010-10-08 2011-10-07 Ｉｌ―17 길항제를 사용하는 건선의 치료 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020147036815A Withdrawn KR20150018595A (ko) 2010-10-08 2011-10-07 Ｉｌ―17 길항제를 사용하는 건선의 치료 방법
KR1020147018691A Active KR101620771B1 (ko) 2010-10-08 2011-10-07 Ｉｌ―17 길항제를 사용하는 건선의 치료 방법

Country Status (28)

Country Link
US (9) US9717791B2 (https=)
EP (5) EP3299390A1 (https=)
JP (2) JP5537740B2 (https=)
KR (3) KR20130110179A (https=)
CN (2) CN103154031A (https=)
AU (1) AU2011311482B2 (https=)
BR (1) BR112013008501A2 (https=)
CA (1) CA2813900C (https=)
CL (1) CL2013000930A1 (https=)
CY (1) CY1119942T1 (https=)
DK (1) DK2625199T3 (https=)
ES (1) ES2660770T3 (https=)
HK (1) HK1247932A1 (https=)
HR (1) HRP20180301T1 (https=)
HU (1) HUE038334T2 (https=)
IL (1) IL225310A (https=)
LT (1) LT2625199T (https=)
MA (1) MA34646B1 (https=)
MX (1) MX356279B (https=)
NO (1) NO2625199T3 (https=)
PH (1) PH12013500660B1 (https=)
PL (1) PL2625199T3 (https=)
PT (1) PT2625199T (https=)
RU (2) RU2665954C1 (https=)
SG (1) SG188979A1 (https=)
SI (1) SI2625199T1 (https=)
TW (2) TWI564022B (https=)
WO (1) WO2012045848A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170045222A (ko) * 2014-08-26 2017-04-26 키린-암젠, 인코포레이티드 항-tnf-알파 항체 요법을 받은 건선 환자의 치료 방법

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
EP2571901B1 (en) 2010-05-20 2019-01-02 Ablynx N.V. Biological materials related to her3
CN103154031A (zh) 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
BR112013011176A2 (pt) 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2783014A1 (en) * 2011-11-21 2014-10-01 Novartis AG Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles
SG11201507482UA (en) * 2013-03-15 2015-10-29 Amgen Inc Methods for treating psoriasis using an anti-il-23 antibody
SG11201507483PA (en) * 2013-03-15 2015-10-29 Amgen Inc Methods for treating crohn's disease using an anti-il23 antibody
WO2015022656A1 (en) 2013-08-15 2015-02-19 Novartis Ag Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
US11421025B2 (en) 2013-12-27 2022-08-23 Osaka University Treatment of IL-17A diseases
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
CA2944605C (en) * 2014-03-31 2023-10-17 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
US10220076B2 (en) 2014-05-15 2019-03-05 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising glucose regulating proteins
US11548940B2 (en) * 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CN115957326A (zh) * 2014-09-10 2023-04-14 诺华股份有限公司 使用il-17拮抗剂抑制银屑病关节炎患者的结构损伤进展
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
EP3265493B1 (en) 2015-03-02 2024-01-10 180 Therapeutics LP Method of treating a localized fibrotic disorder using an il-33 antagonist
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
CN116059350A (zh) * 2015-10-27 2023-05-05 Ucb生物制药有限责任公司 使用抗-il-17a/f抗体的治疗方法
WO2018015880A1 (en) * 2016-07-19 2018-01-25 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
JP2019505516A (ja) * 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
WO2018158741A1 (en) * 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
CN111032691A (zh) * 2017-08-23 2020-04-17 伊莱利利公司 生殖器银屑病的治疗
TWI725532B (zh) * 2018-09-11 2021-04-21 美商美國禮來大藥廠 治療牛皮癬之方法
US20220267432A1 (en) 2019-07-30 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Method for treating autoimmune disease by il-17 antagonist
TW202126329A (zh) 2019-09-20 2021-07-16 瑞士商諾華公司 使用白細胞介素－１７（ｉｌ－１７）拮抗劑治療自體免疫性疾病之方法
WO2022127842A1 (zh) * 2020-12-17 2022-06-23 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用
WO2022184114A1 (zh) * 2021-03-03 2022-09-09 苏州盛迪亚生物医药有限公司 抗il-17抗体治疗自身免疫性疾病和炎症的方法
WO2023186174A1 (en) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Topical formulation comprising an il-17a binding molecule and uses thereof
CN116593718B (zh) * 2023-07-18 2023-09-15 军科正源（北京）药物研究有限责任公司 用于检测司库奇尤单抗抗药性抗体的试剂

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250442A (en) 1993-04-08 1993-10-05 Orestes Cabezas Method of treating rheumatoid arthritis using tetracycline
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US6093745A (en) * 1997-11-25 2000-07-25 Psorx, L.L.C. Methods and composition for treating skin proliferative diseases
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
JP2000186046A (ja) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
JP4159682B2 (ja) 1998-12-22 2008-10-01 株式会社クラレ 止血材
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US8039642B2 (en) 2003-12-09 2011-10-18 Life Technologies Corporation Pyrenyloxysulfonic acid fluorescent agents
TW201705980A (zh) * 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
ES2569409T3 (es) 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
US20080199460A1 (en) * 2005-09-01 2008-08-21 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1963368B3 (en) 2005-12-13 2020-06-10 Eli Lilly And Company Anti-il-17 antibodies
BRPI0706788A2 (pt) 2006-01-31 2011-04-05 Novartis Ag anticorpos antagonistas il-17
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
CA2662350A1 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
RU2367429C2 (ru) 2007-01-30 2009-09-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения псориаза
CA2682292A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
EP2152318A4 (en) * 2007-06-01 2011-12-07 Abbott Biotech Ltd COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
US20100239590A1 (en) 2007-06-20 2010-09-23 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
US7720605B2 (en) 2007-06-22 2010-05-18 Weyerhaeuser Nr Company Identifying vegetation attributes from LiDAR data
RU2341272C1 (ru) 2007-10-22 2008-12-20 Левон Никитович Мкртчян Средство для неспецифической иммунотерапии
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
US20090301682A1 (en) 2008-06-05 2009-12-10 Baker Hughes Incorporated Casting furnace method and apparatus
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
NZ591484A (en) 2008-09-29 2012-09-28 Roche Glycart Ag Antibodies against human il 17 and uses thereof
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
WO2010065491A2 (en) 2008-12-01 2010-06-10 Carolus Therapeutics, Inc. Methods of treating inflammatory disorders
TWI541021B (zh) 2009-03-05 2016-07-11 艾伯維有限公司 Ｉｌ－１７結合蛋白
CN103154031A (zh) 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
BR112013011176A2 (pt) 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
TW201307845A (zh) 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
EP2783014A1 (en) 2011-11-21 2014-10-01 Novartis AG Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles
WO2013158821A2 (en) 2012-04-20 2013-10-24 Novartis Ag Methods of treating ankylosing spondylitis using il-17 antagonists
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA3002622A1 (en) 2015-10-19 2017-04-27 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
US11280479B2 (en) 2017-10-18 2022-03-22 The Sloan Company Sign box light module

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170045222A (ko) * 2014-08-26 2017-04-26 키린-암젠, 인코포레이티드 항-tnf-알파 항체 요법을 받은 건선 환자의 치료 방법

Also Published As

Publication number Publication date
PH12013500660B1 (en) 2017-10-27
US20250161445A1 (en) 2025-05-22
IL225310A (en) 2016-10-31
KR20150018595A (ko) 2015-02-23
BR112013008501A2 (pt) 2016-08-16
SI2625199T1 (en) 2018-03-30
MA34646B1 (fr) 2013-11-02
US11534490B2 (en) 2022-12-27
EP2625199A1 (en) 2013-08-14
HUE038334T2 (hu) 2018-10-29
CL2013000930A1 (es) 2014-03-28
SG188979A1 (en) 2013-05-31
CA2813900A1 (en) 2012-04-12
EP2625199B1 (en) 2017-11-22
TWI564022B (zh) 2017-01-01
US10583190B2 (en) 2020-03-10
IL225310A0 (en) 2013-06-27
HRP20180301T1 (hr) 2018-03-23
US20210113688A1 (en) 2021-04-22
KR101620771B1 (ko) 2016-05-12
EP4137514A1 (en) 2023-02-22
PH12013500660A1 (en) 2013-05-20
NO2625199T3 (https=) 2018-04-21
US20170304439A1 (en) 2017-10-26
US9717791B2 (en) 2017-08-01
MX356279B (es) 2018-05-22
TWI548419B (zh) 2016-09-11
US20130202610A1 (en) 2013-08-08
US12594331B2 (en) 2026-04-07
ES2660770T3 (es) 2018-03-26
JP2014114288A (ja) 2014-06-26
EP3299390A1 (en) 2018-03-28
CN103154031A (zh) 2013-06-12
EP4670788A3 (en) 2026-03-18
CN107029234A (zh) 2017-08-11
US12551554B2 (en) 2026-02-17
RU2591083C2 (ru) 2016-07-10
RU2665954C1 (ru) 2018-09-05
TW201630625A (zh) 2016-09-01
DK2625199T3 (en) 2018-02-26
RU2013120957A (ru) 2014-11-20
JP2013543501A (ja) 2013-12-05
HK1247932A1 (en) 2018-10-05
PT2625199T (pt) 2018-02-28
US12594332B2 (en) 2026-04-07
LT2625199T (lt) 2018-03-12
PL2625199T3 (pl) 2018-04-30
EP3792281A1 (en) 2021-03-17
CA2813900C (en) 2017-01-10
US20230321231A1 (en) 2023-10-12
US20200171147A1 (en) 2020-06-04
EP4670788A2 (en) 2025-12-31
AU2011311482A1 (en) 2013-04-04
CY1119942T1 (el) 2018-12-12
US20210162044A1 (en) 2021-06-03
TW201216984A (en) 2012-05-01
WO2012045848A1 (en) 2012-04-12
US20250161444A1 (en) 2025-05-22
JP5537740B2 (ja) 2014-07-02
AU2011311482B2 (en) 2014-05-29
US20250161443A1 (en) 2025-05-22
KR20140097566A (ko) 2014-08-06
MX2013003916A (es) 2013-06-03

Similar Documents

Publication Publication Date Title
US12594332B2 (en) Methods of treating psoriasis with secukinumab
HK40037862A (en) Methods of treating psoriasis using il-17 antagonists
HK40088403A (en) Methods of treating psoriasis using il-17 antagonists
HK1183673A (en) Methods of treating psoriasis using il-17 antagonists
HK1183673B (en) Methods of treating psoriasis using il-17 antagonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130507

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A107 Divisional application of patent
A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20140704

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140704

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20140704

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140730

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20141126

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140730

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20141229

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20141126

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20140704

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20150129

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20141229

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20141126

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20140730

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20140704

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20150227

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20150129

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20141126

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20150715

Appeal identifier: 2015101001110

Request date: 20150227

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20150227

Effective date: 20150715

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20150715

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20150227

Decision date: 20150715

Appeal identifier: 2015101001110

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20150804

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20150804

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2015101001110

Request date: 20150227

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20150715

WITB Written withdrawal of application